(ELV) Elevance Health - Ratings and Ratios
Health Plans, Pharmacy Services, Specialty Insurance, Care Management
ELV EPS (Earnings per Share)
ELV Revenue
Description: ELV Elevance Health
Elevance Health, Inc. (NYSE: ELV) is a U.S. health-benefits company organized into four segments-Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a broad portfolio of health plans (individual, employer-group, Medicare, Medicaid, and Federal Employee Program) and supplemental products such as dental, vision, and stop-loss insurance, while also operating a full-service pharmacy business that includes home delivery, specialty pharmacy, formulary management, and infusion services. Through its HealthOS platform, Elevance provides data-driven care-management tools, behavioral health, virtual care, payment-integrity solutions, and post-acute services, all under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands.
Key recent metrics underline the company’s scale and growth trajectory: FY 2023 revenue reached approximately $152 billion, with a medical loss ratio (MLR) of 86.5%-a benchmark for cost efficiency in managed care. Enrollment in Medicare Advantage grew 9% YoY, reflecting the aging U.S. population, while the pharmacy segment saw a 5% increase in specialty drug spend, driven by rising prevalence of chronic conditions. Sector-wide, inflationary pressure on medical services and ongoing regulatory reforms (e.g., ACA adjustments and Medicaid expansion in several states) are primary drivers of both premium growth and cost-containment initiatives.
For a deeper, data-rich analysis of Elevance Health’s valuation and risk profile, you may find ValueRay’s platform useful as a next step in your research.
ELV Stock Overview
| Market Cap in USD | 79,542m |
| Sub-Industry | Managed Health Care |
| IPO / Inception | 2001-01-02 |
ELV Stock Ratings
| Growth Rating | -41.4% |
| Fundamental | 70.1% |
| Dividend Rating | 70.3% |
| Return 12m vs S&P 500 | -30.8% |
| Analyst Rating | 4.41 of 5 |
ELV Dividends
| Dividend Yield 12m | 1.94% |
| Yield on Cost 5y | 2.47% |
| Annual Growth 5y | 14.45% |
| Payout Consistency | 100.0% |
| Payout Ratio | 20.5% |
ELV Growth Ratios
| Growth Correlation 3m | 91.5% |
| Growth Correlation 12m | -64.5% |
| Growth Correlation 5y | 25.6% |
| CAGR 5y | -10.79% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.21 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.62 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | -37.76 |
| Beta | 0.590 |
| Volatility | 33.77% |
| Current Volume | 1439.7k |
| Average Volume 20d | 1769k |
| Stop Loss | 338.3 (-3%) |
| Signal | -0.18 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (5.36b TTM) > 0 and > 6% of Revenue (6% = 11.36b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 3.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6.95% (prev 7.46%; Δ -0.51pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 6.45b > Net Income 5.36b (YES >=105%, WARN >=100%) |
| Net Debt (21.63b) to EBITDA (9.87b) ratio: 2.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.8m) change vs 12m ago -3.26% (target <= -2.0% for YES) |
| Gross Margin 54.59% (prev 28.34%; Δ 26.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 161.1% (prev 152.0%; Δ 9.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.33 (EBITDA TTM 9.87b / Interest Expense TTM 1.32b) >= 6 (WARN >= 3) |
Altman Z'' 2.61
| (A) 0.11 = (Total Current Assets 56.98b - Total Current Liabilities 43.83b) / Total Assets 121.94b |
| (B) 0.29 = Retained Earnings (Balance) 35.55b / Total Assets 121.94b |
| (C) 0.07 = EBIT TTM 8.39b / Avg Total Assets 117.46b |
| (D) 0.45 = Book Value of Equity 34.79b / Total Liabilities 78.09b |
| Total Rating: 2.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.13
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 5.28% = 2.64 |
| 3. FCF Margin 2.82% = 0.71 |
| 4. Debt/Equity 0.69 = 2.27 |
| 5. Debt/Ebitda 2.19 = -0.37 |
| 6. ROIC - WACC (= 2.64)% = 3.30 |
| 7. RoE 12.51% = 1.04 |
| 8. Rev. Trend 91.76% = 6.88 |
| 9. EPS Trend 13.33% = 0.67 |
What is the price of ELV shares?
Over the past week, the price has changed by -1.27%, over one month by +13.06%, over three months by +15.94% and over the past year by -20.08%.
Is Elevance Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ELV is around 311.25 USD . This means that ELV is currently overvalued and has a potential downside of -10.76%.
Is ELV a buy, sell or hold?
- Strong Buy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 375.8 | 7.8% |
| Analysts Target Price | 375.8 | 7.8% |
| ValueRay Target Price | 339.8 | -2.6% |
Last update: 2025-10-14 02:27
ELV Fundamental Data Overview
P/E Trailing = 14.9932
P/E Forward = 10.9529
P/S = 0.4203
P/B = 1.7523
P/EG = 0.8759
Beta = 0.59
Revenue TTM = 189.25b USD
EBIT TTM = 8.39b USD
EBITDA TTM = 9.87b USD
Long Term Debt = 28.18b USD (from longTermDebt, last quarter)
Short Term Debt = 2.01b USD (from shortTermDebt, last quarter)
Debt = 30.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.63b USD (from netDebt column, last quarter)
Enterprise Value = 101.17b USD (79.54b + Debt 30.19b - CCE 8.56b)
Interest Coverage Ratio = 6.33 (Ebit TTM 8.39b / Interest Expense TTM 1.32b)
FCF Yield = 5.28% (FCF TTM 5.34b / Enterprise Value 101.17b)
FCF Margin = 2.82% (FCF TTM 5.34b / Revenue TTM 189.25b)
Net Margin = 2.83% (Net Income TTM 5.36b / Revenue TTM 189.25b)
Gross Margin = 54.59% ((Revenue TTM 189.25b - Cost of Revenue TTM 85.94b) / Revenue TTM)
Gross Margin QoQ = 15.62% (prev 89.81%)
Tobins Q-Ratio = 0.83 (Enterprise Value 101.17b / Total Assets 121.94b)
Interest Expense / Debt = 1.13% (Interest Expense 341.0m / Debt 30.19b)
Taxrate = 23.91% (548.0m / 2.29b)
NOPAT = 6.39b (EBIT 8.39b * (1 - 23.91%))
Current Ratio = 1.30 (Total Current Assets 56.98b / Total Current Liabilities 43.83b)
Debt / Equity = 0.69 (Debt 30.19b / totalStockholderEquity, last quarter 43.72b)
Debt / EBITDA = 2.19 (Net Debt 21.63b / EBITDA 9.87b)
Debt / FCF = 4.05 (Net Debt 21.63b / FCF TTM 5.34b)
Total Stockholder Equity = 42.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.40% (Net Income 5.36b / Total Assets 121.94b)
RoE = 12.51% (Net Income TTM 5.36b / Total Stockholder Equity 42.83b)
RoCE = 11.82% (EBIT 8.39b / Capital Employed (Equity 42.83b + L.T.Debt 28.18b))
RoIC = 8.81% (NOPAT 6.39b / Invested Capital 72.47b)
WACC = 6.17% (E(79.54b)/V(109.73b) * Re(8.19%) + D(30.19b)/V(109.73b) * Rd(1.13%) * (1-Tc(0.24)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 77.39% ; FCFE base≈3.53b ; Y1≈3.44b ; Y5≈3.47b
Fair Price DCF = 266.9 (DCF Value 60.10b / Shares Outstanding 225.2m; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: 13.33 | EPS CAGR: 6.01% | SUE: -0.21 | # QB: 0
Revenue Correlation: 91.76 | Revenue CAGR: 8.34% | SUE: 1.57 | # QB: 4
Additional Sources for ELV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle